101 related articles for article (PubMed ID: 9763220)
1. Modifications of oxido-reductase activities in adriamycin-resistant leukaemia K562 cells.
Denis-Gay M; Petit JM; Mazat JP; Ratinaud MH
Biochem Pharmacol; 1998 Aug; 56(4):451-7. PubMed ID: 9763220
[TBL] [Abstract][Full Text] [Related]
2. Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells.
Grandjean F; Brémaud L; Robert J; Ratinaud MH
Biochem Pharmacol; 2002 Mar; 63(5):823-31. PubMed ID: 11911833
[TBL] [Abstract][Full Text] [Related]
3. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H
Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
[TBL] [Abstract][Full Text] [Related]
4. The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen F
Leuk Lymphoma; 2015 Mar; 56(3):755-62. PubMed ID: 24996439
[TBL] [Abstract][Full Text] [Related]
5. B4GALT1 gene knockdown inhibits the hedgehog pathway and reverses multidrug resistance in the human leukemia K562/adriamycin-resistant cell line.
Zhou H; Zhang Z; Liu C; Jin C; Zhang J; Miao X; Jia L
IUBMB Life; 2012 Nov; 64(11):889-900. PubMed ID: 23024026
[TBL] [Abstract][Full Text] [Related]
6. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
[TBL] [Abstract][Full Text] [Related]
7. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
[TBL] [Abstract][Full Text] [Related]
8. Effects of hemin on apoptosis, suppression of cytochrome c oxidase gene expression, and bone-marrow toxicity induced by doxorubicin (adriamycin).
Papadopoulou LC; Tsiftsoglou AS
Biochem Pharmacol; 1996 Sep; 52(5):713-22. PubMed ID: 8765469
[TBL] [Abstract][Full Text] [Related]
9. [Correlation between reversing effect of cepharanthine hydrochloride on multidrug resistance and P-glycoprotein expression and function of K562/ADR cells].
Peng YM; Wang N; Wang YF; Han L; Zhang Y; Jiang JH; Zhou YB; Wang QD
Yao Xue Xue Bao; 2012 May; 47(5):594-9. PubMed ID: 22812001
[TBL] [Abstract][Full Text] [Related]
10. [Reversal effect of berbamine on multidrug resistance of K562/A02 cells and its mechanism].
Han YQ; Yuan JY; Shi YJ; Zhu Y; Wu SL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):604-8. PubMed ID: 14706144
[TBL] [Abstract][Full Text] [Related]
11. Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells.
Kurosawa M; Okabe M; Hara N; Kawamura K; Suzuki S; Sakurada K; Asaka M
Ann Hematol; 1996 Jan; 72(1):17-21. PubMed ID: 8605275
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle.
Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ
Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184
[TBL] [Abstract][Full Text] [Related]
14. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
15. Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of gamma-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells.
Asano T; Tsutsuda-Asano A; Fukunaga Y
Cancer Chemother Pharmacol; 2009 Sep; 64(4):715-21. PubMed ID: 19153736
[TBL] [Abstract][Full Text] [Related]
16. [Development of a K562 multidrug-resistant cell line and study on proteins with altered expression].
Wang Y; Cao J; Zeng S
Shi Yan Sheng Wu Xue Bao; 2003 Oct; 36(5):342-6. PubMed ID: 14724945
[TBL] [Abstract][Full Text] [Related]
17. [Studies on the microtubules assembly of multidrug-resistant human leukemic cells].
Hara N
Hokkaido Igaku Zasshi; 1995 Jul; 70(4):573-89. PubMed ID: 7590604
[TBL] [Abstract][Full Text] [Related]
18. In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells.
Zhang L; Wang Z; Khishignyam T; Chen T; Zhou C; Zhang Z; Jin M; Wang R; Qiu Y; Kong D
Biomed Pharmacother; 2018 Jul; 103():1069-1078. PubMed ID: 29710665
[TBL] [Abstract][Full Text] [Related]
19. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.
Wang R; Shao F; Liu Z; Zhang J; Wang S; Liu J; Liu H; Chen H; Liu K; Xia M; Wang Y
Chem Biol Interact; 2013 Sep; 205(1):1-10. PubMed ID: 23777986
[TBL] [Abstract][Full Text] [Related]
20. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity.
Song YN; Guo XL; Zheng BB; Liu XY; Dong X; Yu LG; Cheng YN
Toxicol In Vitro; 2011 Jun; 25(4):937-43. PubMed ID: 21402141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
